Novartis consensus picture on SIX, analysts keep a neutral view on the stock

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 13:20.

Novartis (CH0012005267) starts the week with a clear analyst consensus around its listing on the SIX Swiss Exchange. The pharma group draws a neutral stance from a broad base of coverage with tightly clustered 12-month price targets, according to a consensus overview dated late June 2026 Investing.com consensus data for Novartis.

What analysts currently say

The latest consensus shows 21 analysts covering Novartis, with the average recommendation sitting at Neutral, underscoring a balanced view between upside and downside potential Investing.com breakdown of ratings and targets. Their average 12-month price target is reported at 125.17 Swiss francs, with a high estimate of about 144.39 francs and a low estimate near 97.98 francs, pointing to a relatively narrow spread for a large-cap pharma stock.

Based on the current spot price used in that consensus snapshot, the implied potential downside stands at roughly 0.15 percent for the Novartis shares Analyst target versus latest Novartis quote. This muted risk profile reflects the company’s established position in the global pharmaceuticals sector and stable cash generation, even as investors weigh patent cycles and competition from peers such as Novo Nordisk in diabetes and obesity therapies TradingKey data on Novartis and global pharma peers.

Monday focus on consensus and peers

On Monday, the focus for many investors is how Novartis sits within the broader European healthcare universe and major indices. Novartis is a heavyweight constituent of Swiss benchmarks and is represented in international indices such as the STOXX Europe 50 and DJ Global Titans 50, making the neutral analyst stance relevant for benchmark-driven portfolios Finanzen100 profile of Novartis in European indices.

Consensus-based price targets around 125 francs compare with recent indications for the ADR traded on the NYSE under the ticker NVS, where the shares last closed at 155.41 US dollars on June 26, 2026, giving the group a market capitalization above 290 billion dollars TradingKey quote and market cap for Novartis ADR. This dual exposure on SIX and NYSE contributes to high liquidity and allows analyst views to feed into both European and US investor decisions.

The business behind the stock

Novartis generates its revenue from a broad portfolio of innovative prescription medicines spanning oncology, immunology, cardiovascular disease and neuroscience. Key franchises include therapies such as Cosentyx for immune-mediated conditions, Entresto for heart failure, and a range of oncology treatments that anchor its pipeline and support long-term cash flows Novartis Investor Relations overview of core therapeutic areas.

Where the Novartis shares trade today

The Novartis shares (CH0012005267) last traded on the SIX Swiss Exchange at 125.36 Swiss francs as of 2026-06-26, 16:30, reflecting a large-cap valuation in line with the consensus picture from analysts Latest Novartis SIX quote aligned with consensus data.

Disclaimer: This article provides factual information on the Novartis shares and does not contain investment advice or personal recommendations. Investors should base decisions on their own research and, where appropriate, seek professional counsel.